menu
    • menu

    Company profile for ORIC Pharmaceuticals

    NEW Drugs in Dev: 5
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antago...
    ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ORIC PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    240 E. Grand Ave, 2nd Floor South San Francisco, CA 94080
    Telephone
    Telephone
    (650) 388-5600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://oricpharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ORIC Pharma Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
    ORIC Pharma Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)

    01 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/01/3286230/0/en/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html

    GLOBENEWSWIRE
    01 May 2026
    Share Share
    ORIC Pharma Highlights Rinzimetostat's Prostate Cancer Potential
    ORIC Pharma Highlights Rinzimetostat's Prostate Cancer Potential

    19 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7187990

    FIRSTWORD PHARMA
    19 Apr 2026
    Share Share
    ORIC Pharma Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
    ORIC Pharma Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)

    03 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/03/3268139/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    03 Apr 2026
    Share Share
    ORIC Pharmaceuticals Picks Rinzimetostat RP3D for Phase 3
    ORIC Pharmaceuticals Picks Rinzimetostat RP3D for Phase 3

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3266009/0/en/ORIC-Pharmaceuticals-Reports-Selection-of-Rinzimetostat-RP3D-in-Combination-with-Darolutamide-for-Himalayas-1-Phase-3-Global-Study-with-Dose-Optimization-Data-Supporting-Its-Potent.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share
    ORIC To Report Rinzimetostat Ph1b Combo Data In mCRPC
    ORIC To Report Rinzimetostat Ph1b Combo Data In mCRPC

    27 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/27/3263751/0/en/ORIC-Pharmaceuticals-to-Report-Combination-Dose-Optimization-Data-From-Phase-1b-Trial-of-Rinzimetostat-in-Patients-with-mCRPC.html

    GLOBENEWSWIRE
    27 Mar 2026
    Share Share
    ORIC Pharma Unveils (ORIC-944) Preclinical Data At AACR 2026
    ORIC Pharma Unveils (ORIC-944) Preclinical Data At AACR 2026

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3257727/0/en/ORIC-Pharmaceuticals-Announces-Preclinical-Rinzimetostat-ORIC-944-Presentations-at-the-2026-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search